Zydus Lifesciences Ltd

Zydus Lifesciences and Guardant Health, Inc., a leading precision oncology company, have an exclusive agreement to make the Shield' Multi-Cancer Detection (MCD) test available in India, for which Zydus has signed a Memorandum of Understanding (MoU) with Apollo Hospitals to offer the test in the territory. The Shield MCD test is a methylation-based blood test for the detection of multiple cancer types including bladder, colorectal, breast, prostate, oesophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older and who are at typical average risk for cancer. With just a blood draw, the test screens for 10 of the most common cancers, many of which have high mortality rates in India. The test has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA), recognising its potential to provide more effective screening for cancers than existing options.

Shares of Apollo Hospitals Enterprise also gained 1.73% to Rs 8,848 on the BSE. Under an exclusive agreement with Zydus Lifesciences, Guardant Health will commercialise the Shield MCD test in India, while Apollo Hospitals will offer the test through its healthcare network. The Shield MCD test is a methylation-based blood test for the detection of multiple cancer types including bladder, colorectal, breast, prostate, oesophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older and who are at typical average risk for cancer. The test has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA), recognising its potential to provide more effective screening for cancers than existing options. Speaking on this development, Dr. Prathap C. Reddy, chairman, Apollo Hospitals Group, said, At Apollo, we have long believed that the most effective healthcare is proactive healthcare. The future of medicine lies not only in treating disease, but in preventing it and detecting it at its earliest, most treatable stages. Cancer continues to be one of the greatest health challenges facing societies worldwide, and expanding access to timely, reliable screening, is critical to reducing its impact. Our collaboration with Zydus Lifesciences marks an important milestone in advancing accessible, patient-friendly cancer screening solutions for the people of India.' Dr. Sharvil Patel, managing director, Zydus Lifesciences, said, 'As India's leading oncology company, we are reimagining the role of diagnostics in cancer care. We are pleased to partner with Apollo Hospitals and Guardant Health to introduce Shield MCD in India, expanding access to an innovative screening technology that complements existing screening pathways.' Simranjit Singh, chief executive officer, Guardant Health AMEA added, We are pleased to bring the Shield Multi-Cancer Detection (MCD) test to India through Apollo Cancer Centres and our longstanding commercial partner Zydus Lifesciences. Earlier detection has the potential to transform cancer outcomes, and Shield MCD represents an important advancement in helping identify cancer-associated signals through a single blood draw.' Zydus Lifesciences is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. Apollo Hospitals was established in 1983 by Dr. Prathap C Reddy, renowned architect of modern healthcare in India. It has a robust presence across the healthcare ecosystem, including Hospitals, Pharmacies, Primary Care & Diagnostic Clinics and several Retail Health models. Powered by Capital Market - Live

Zydus Lifesciences and Sunshine Healthcare today announced the setting up of a strategic joint venture company - Zydus Sunshine Lifesciences, with an investment commitment of over USD 20 million to establish a pharmaceutical manufacturing facility in Sri Lanka, strengthening local production and reducing import dependence. The facility, to be located at the Board of Investment zone in Horana, will be developed on nearly four acres of land. The foundation stone was laid today, marking the formal commencement of the project. The plant will focus on manufacturing pharmaceutical products for Sri Lanka's retail market, improving access to high-quality medicines while supporting national supply chain resilience. The joint venture combines Zydus' global expertise in pharmaceutical manufacturing and technical know-how with Sunshine's strong local market presence and healthcare distribution capabilities. The partnership will support technology transfer, build local manufacturing capability, and create employment, contributing to the long-term development of Sri Lanka's healthcare ecosystem. The initiative comes at a critical time as Sri Lanka prioritises domestic production in essential sectors. By strengthening local pharmaceutical manufacturing capacity, the venture is expected to enhance supply security, reduce reliance on imports, and improve the affordability and availability of medicines.

Zydus Lifesciences has received a Warning Letter from the United States Food and Drug Administration (USFDA) relating to its formula on manufacturing facility located at Baddi, Himachal Pradesh. The Warning Letter was issued in response to a request for records pursuant to sec on 704(a)(4) of the Federal Food, Drug, and Cosmetic Act, and does not pertain to any onsite inspection of the facility by the USFDA. The communication references technical observations regarding the use of purified talc that did not meet the current United States Pharmacopeia (USP) requirements. The company added that the said Warning Letter will not impact current operations and supplies from the Baddi site. The Baddi manufacturing facility was last subjected to an on-site inspection by the USFDA in August 2025. Subsequent to the conclusion of the inspec on, the Company received the Establishment Inspection Report (EIR) in October 2025, with the final compliance status classified as Voluntary Ac on Indicated (VAI).

The warning letter was issued in response to a request for records pursuant to a section of the Federal Food, Drug, and Cosmetic Act, and does not pertain to any on-site inspection of the facility by the US FDA. The communication references technical observations regarding the use of purified talc that did not meet the current United States Pharmacopeia (USP) requirements. We believe that the said warning letter will not impact current operations and supplies from the Baddi site,' Zydus Lifesciences said in a statement. The Baddi manufacturing facility was last subjected to an on-site inspection by the USFDA in August 2025. Subsequent to the conclusion of the inspection, the company received the establishment inspection report (EIR) in October 2025, with the final compliance status classified as voluntary action indicated (VAI). Zydus Lifesciences is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The company's consolidated net profit jumped 8.68% to Rs 1,272.5 crore on 16.22% increase in revenue from operations to Rs 7,587 crore in Q4 FY26 over Q4 FY25. Powered by Capital Market - Live

Zydus Lifesciences Ltd rose for a fifth straight session today. The stock is quoting at Rs 1105.45, up 1.81% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.24% on the day, quoting at 23849.9. The Sensex is at 75777.13, down 0.12%. Zydus Lifesciences Ltd has added around 23.94% in last one month. Meanwhile, Nifty Pharma index of which Zydus Lifesciences Ltd is a constituent, has added around 6.44% in last one month and is currently quoting at 24716, up 0.2% on the day. The volume in the stock stood at 14.03 lakh shares today, compared to the daily average of 23 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 1114.05, up 2.08% on the day. Zydus Lifesciences Ltd is up 18.87% in last one year as compared to a 3.64% fall in NIFTY and a 15.5% fall in the Nifty Pharma index.The PE of the stock is 29.59 based on TTM earnings ending March 26.Powered by Capital Market - Live

Zydus Lifesciences and its various subsidiaries has invested balance 9.01 crore for subscription of 90,17,848 equity shares under Tranche 2, 3 and 4 of Torrent Urja 25, representing 22.06% of its paid-up share capital. Pursuant to the same, the transaction of subscription of shares of Torrent Urja 25 is consummated on 19 May 2026. In June 2025 under Tranche 1, the company and its subsidiaries had invested Rs 3.86 crore for subscription of 38,64,792 equity shares of Torrent Urja 25, representing 22.06% of its paid-up share capital.

Profit before exceptional item and tax (PBT) increased 8.75% YoY to Rs 2,057.2 crore in Q4 FY26. During the quarter, the company reported an exceptional item of Rs 397.5 crore, primarily on account of a one-time expenditure related to the Mirabegron litigation settlement. EBITDA stood at Rs 2,554.4 crore in Q4 FY26, registering the growth of 20.2% compared with Rs 2,125.5 crore in Q4 FY25. EBITDA margin improved to 33.7% in Q4 FY26 as against 32.6% in Q4 FY25. The company's organic capital expenditure for the quarter stood at Rs 357.7 crore. Revenue from India formulation business jumped 14% YoY to Rs 1,752.8 crore, contributing 24% to consolidated revenue. Branded business grew faster than the market with 15% YoY growth. North America formulation business registered revenues of Rs 2,952.3 crore, down 6% YoY and accounted for 40% of consolidated revenue. In constant currency terms, the business posted revenue of $323 milion. Revenue from international markets formulation business stood at Rs 804.1 crore, up 45% YoY. The business accounted for 11% of consolidated revenues. The growth was broad-based across regions, led by robust demand in emerging markets and Europe, aided by focused execution Revenue from consumer wellness business climbed 61% YoY to Rs 1,463.3 crore. Domestic business grew by 1.7% YoY. Within the domestic business, the seasonal brands declined by 9.8%, whereas the skin & hair care brands and food & nutrition brands registered 39.7% and 9.4% YoY growth respectively. On full year basis, the company's consolidated net profit jumped 11.37% to Rs 5,040 crore in FY26 compared with Rs 4,525.5 crore in FY25. Revenue from operations increased 16.81% to Rs 27,148.4 crore in FY26 compared with Rs 23,241.5. Meanwhile, the company's board recommended a final dividend of Re 1 per equity share of face value Re 1 each for FY26, subject to shareholders' approval at the forthcoming Annual General Meeting (AGM) scheduled on Tuesday, 11 August 2026. The company has fixed 24 July 2026 as the record date for determining shareholders eligible for the dividend. Further, the board also approved a share buyback of up to 95,65,217 equity shares aggregating up to Rs 1,100 crore at a price of Rs 1,150 per share, representing a premium of 16.02% over the stock's closing price of Rs 991.20 on 18 May 2026. The record date for the buyback has been fixed as 29 May 2026. As on 15 May 2026, promoters and the promoter group held a 74.9950% stake in the company. Zydus Lifesciences is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.Powered by Capital Market - Live

Zydus Lifesciences announced that the Board of Directors of the Company at its meeting held on 19 May 2026, inter alia, have recommended the final dividend of Rs 1 per equity Share (i.e. 100%) , subject to the approval of the shareholders.

Zydus Lifesciences announced that the Annual General Meeting(AGM) of the company will be held on 11 August 2026.